Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5808127 | 0.82 | LMNA (0.55) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL385724 | 0.82 | LMNA (0.55) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL28644100 | 0.80 | LMNA (0.52) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL1507296 | 0.80 | ALDH1A1 (0.48) | LMNABLMALDH1A1TSHRHPGD | |
| SCHEMBL10930855 | 0.79 | LMNA (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL4093324 | 0.78 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL12610848 | 0.78 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL1935211 | 0.78 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL10625734 | 0.78 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL11826053 | 0.78 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008068-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2020-12-30 | — | — | EP | disclosed |
| US-9505769-B2 | Tetraaza-cyclopenta[a]indenyl derivatives | ASCENEURON SA (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20160137648-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2016-05-19 | — | — | US | disclosed |
| EP-3008068-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | Asceneuron SA (CH) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014198808-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2014-12-18 | — | — | WO | disclosed |
| EP-2813505-A1 | Tetraaza-cyclopenta[a]indenyl derivatives | Asceneuron SA (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-4849172-A | Optical sensor | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0243116-A2 | Optical sensor | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137648-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | CHRM1, CHRM2, CHRM3 | LMNA 4307/4885KMT2A 2888/4885MEN1 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.